Summary
Vertex Pharmaceuticals Inc. reported its financial results for the period ending June 30, 2015. The company experienced a significant increase in product revenues, primarily driven by KALYDECO, but this was offset by decreases in royalty and collaborative revenues. Despite revenue growth, Vertex continues to operate at a net loss, which widened slightly compared to the prior year period due to increased operating costs and expenses, particularly in sales, general, and administrative functions. A key development during the period was the significant investment in a collaboration with Parion Sciences for the development of ENaC inhibitors, which also led to a substantial increase in intangible assets and goodwill on the balance sheet. The company also achieved a significant milestone with the FDA approval of ORKAMBI (lumacaftor in combination with ivacaftor) in July 2015, shortly after the reporting period. While this is a crucial step towards future revenue generation, the company anticipates significant reimbursement discussions in ex-U.S. markets, suggesting that ORKAMBI's full revenue potential may take time to materialize globally. Overall, Vertex is investing heavily in its research and development pipeline, particularly in cystic fibrosis, while managing its financial resources to support ongoing operations and future commercialization efforts.
Financial Highlights
49 data points| Revenue | $166.08M |
| Cost of Revenue | $15.41M |
| Gross Profit | $150.67M |
| R&D Expenses | $223.86M |
| SG&A Expenses | $94.39M |
| Operating Expenses | $337.24M |
| Operating Income | -$171.16M |
| Net Income | -$188.85M |
| EPS (Basic) | $-0.78 |
| EPS (Diluted) | $-0.78 |
| Shares Outstanding (Basic) | 240.76M |
| Shares Outstanding (Diluted) | 240.76M |
Key Highlights
- 1Total revenues increased by 20% to $166.1 million for the three months ended June 30, 2015, compared to $138.4 million in the prior year period.
- 2Product revenues, driven by KALYDECO, rose by 31% to $160.4 million for the three months ended June 30, 2015.
- 3Net loss attributable to Vertex was $188.8 million for the three months ended June 30, 2015, an increase from $159.4 million in the same period last year.
- 4The company incurred significant research and development expenses of $223.9 million for the three months ended June 30, 2015, largely consistent with the prior year period.
- 5Sales, general and administrative expenses increased by 22% to $94.4 million for the three months ended June 30, 2015, reflecting investments in commercial support and launch preparations.
- 6Vertex entered into a significant collaboration with Parion Sciences in June 2015, involving an upfront payment of $80 million and potential milestone/royalty payments, resulting in the consolidation of Parion as a VIE and the recognition of substantial intangible assets.
- 7The company had $1.02 billion in cash, cash equivalents, and marketable securities as of June 30, 2015, a decrease from the prior year-end due to R&D expenses, SG&A, and the Parion collaboration payment.